Login or sign up
For business

Dalcor pharmaceuticals

4.1· 13 reviews
Average ratingGreat
4.1/ 5

Based on 13 reviews

538%
431%
331%
20%
10%
Ask AI

Ask AI about Dalcor pharmaceuticals

Generated with AI from 13 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Chris Heuer
Reviews 1

I recently came across a pharmaceutical company that has impressed me with their innovation and commitment to delivering high-quality products. The website of this company, dalcorpharma.com, is user-friendly, providing all the necessary information about their products and services in a clear and concise manner. What sets them apart is their dedication to research and development, evident in the diverse range of products they offer. The quality of their offerings is unparalleled, consistently surpassing my expectations. Their customer support team is highly responsive and knowledgeable, always ready to assist and answer any inquiries. Moreover, their commitment to ethical practices and sustainability is commendable. I am confident that the remarkable efficiency and effectiveness of this company will continue to benefit countless individuals and healthcare providers.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Dalcor pharmaceuticals

DalCor is developing precision treatments for cardiovascular disease by genetically targeting patients that will derive clinical benefits. The company’s first development program, dalcetrapib, is intended to reduce cardiovascular events in a genetically distinct subset of patients.

A pharmacogenomics analysis which was performed on 5,749 of the 17,000-patient dal-Outcomes study showed that patients with acute coronary syndrome (ACS) having an AA polymorphism at the rs1967309 location in the ADCY9 gene had significantly fewer cardiovascular events when treated with dalcetrapib, a CETP inhibitor, than with placebo. DalCor has secured a world-wide exclusive license from Roche for dalcetrapib together with rights to the ADCY9 genetic marker.

Address
1010 sherbrooke street west
Categories
Pharmaceuticals